In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Precipio (PRPO – Research Report), with a price target of $4.00. The company’s shares opened today at $1.32.
According to TipRanks, McCarthy is an analyst with an average return of -36.2% and a 17.69% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Atossa Therapeutics, Capricor Therapeutics, and VistaGen Therapeutics.
Precipio has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
See the top stocks recommended by analysts >>
PRPO market cap is currently $30.43M and has a P/E ratio of -2.82.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Precipio, Inc. is a cancer diagnostics company, which engages in the development and provision of a platform designed to eradicate the problem of misdiagnosis. Its products and services include MX-ICP and HemeScreen HRM kits, SmartPath, SmartGen, and ICP liquid biopsy testing. The company was founded in March 1997 and is headquartered in New Haven, CT.
Read More on PRPO:
- Surrey Bancorp Announces Third Quarter Cash Dividend of $0.105 per Common Share
- Analysts’ Opinions Are Mixed on These Materials Stocks: MAG Silver (MAG) and Silgan Holdings (SLGN)
- Walmart (WMT) Gets a Buy from BMO Capital
- Here’s Why Eargo Stock Has Gained 184% in Two Days
- Foresight Solar & Technology VCT plc – Annual Report
